Analysis and Comparison of Foreign and Chinese Patent Applications in Chimeric Antigen Receptor T Cell (CAR-T) Technology

doi:10.13523/j.cb.20180414

China Biotechnology

2018, Vol. 38

Issue (4): 107-114 DOI: 10.13523/j.cb.20180414

Analysis and Comparison of Foreign and Chinese Patent Applications in Chimeric Antigen Receptor T Cell (CAR-T) Technology

Qing BI(

),Lin SUN

Pantent Examination Cooperation Tianjin Center of The Patent Office SIPO, Tianjin 300304, China

Download:

HTML

PDF(2128KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has been a newly efficacious treatment for malignant tumor. The information on the development trend of domestic and global patent applications, major patent applicants and patent application by regions are acquired by searching and analyzing the patent application documents with respect to CAR-T. Particularly, the R&D technical roadmap of Novartis which received first ever FDA approval for a CAR-T cell therapy and the patent application layout of major domestic research institutions are summarized.

Key words： CAR-T Patent analysis Novartis

Received: 28 October 2017 Published: 08 May 2018

ZTFLH:

Q939.91

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Qing BI
	Lin SUN

Cite this article:

Qing BI,Lin SUN. Analysis and Comparison of Foreign and Chinese Patent Applications in Chimeric Antigen Receptor T Cell (CAR-T) Technology. China Biotechnology, 2018, 38(4): 107-114.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20180414 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I4/107

Fig.1 Global development trend of patent application related CAR-T

Fig.2 Global geographical distribution of patent application related CAR-T

Table 1 The major patent applicants on CAR-T R&D field

Fig.3 Patent application distribution evolution diagram of Novartis on CAR-T

Fig.4 The development trend of patent applications on CAR-T in China

Table 2 The major patent applicants in the field of CAR-T in China


[1]	Almasbak H, Aarvak T, Vemuri M C . CAR T cell therapy: a game changer in cancer treatment. Journal of Immunology Research, 2016,2016:5474602.

[2]	Gross G, Waks T, Eshhar Z . Expression of immunoglobulin T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of The National Academy of Sciences of The United States of America, 1989,86(24):10024-10028. doi: 10.1073/pnas.86.24.10024 pmid: 2513569

[3]	Chmielewski M, Hombach A A, Abken H . Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunological Reviews, 2014,257(1):83-90. doi: 10.1111/imr.12125 pmid: 24329791

[1]	CHEN Ying,LI Qian. Patent Analysis on the Development Trend of Industrial Application of Special Yeast[J]. China Biotechnology, 2021, 41(4): 91-99.

[2]	JIANG Tian,ZHANG Chao,LIU Hui-zhou. Development Trends Analysis of Microbial Fuel Cell[J]. China Biotechnology, 2020, 40(1-2): 189-197.

[3]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[4]	HUANG Peng-fei,CHEN Yun,LU Jiao,MAO Kai-yun,YUAN Yin-chi. Development Situation and Suggestions of Biomedicine Patent-intensive Industry, Based on the Case Study of Shanghai[J]. China Biotechnology, 2020, 40(12): 108-116.

[5]	XIAO Xue-jun,TANG Qi,XINHUA Nabi. CAR-T Therapy Targeting Tumor Microenvironment[J]. China Biotechnology, 2020, 40(12): 67-74.

[6]	Yu-sheng OU,Hong-jun ZHENG,Shi ZHONG,Yi LI. TAEST16001:TCR Affinity Enhanced Specific-T-cell Therapy[J]. China Biotechnology, 2019, 39(2): 49-61.

[7]	Lin YU,Jian-hua WANG,Liang-peng GE. Advance in Immunotherapy Research of Hepatocellular Carcinoma Targeting Glypican-3[J]. China Biotechnology, 2017, 37(12): 90-95.

[8]	XIA Tai-shou, WANG Yuan-lei, TIAN Li-li. Reserch on Present Situation and Countermeasure of Jiangsu Biomedical Business Based on Patent[J]. China Biotechnology, 2016, 36(8): 123-130.

[9]	LI Dong qiao, GUO Wen jiao, CHEN Fang. Research on Development Trend of Transgenic Medicinal Plant Technology Based on Patent Analysis[J]. China Biotechnology, 2016, 36(11): 98-108.

[10]	ZHAO Hui-cun. Research and Development Trend of Biological Reactor Technology Based on Patent Visualization[J]. China Biotechnology, 2016, 36(1): 115-121.

[11]	WU Xue-yan, HAN Xue-bing, DAI Lei. Patentometric Analysis of Transgenic Soybean Technology Based on DII[J]. China Biotechnology, 2013, 33(3): 143-148.

Viewed

Full text

Abstract

Cited

Shared

Discussed